WO2018130170A1 - 一种肿瘤坏死因子alpha的高亲和性肽及其应用 - Google Patents

一种肿瘤坏死因子alpha的高亲和性肽及其应用 Download PDF

Info

Publication number
WO2018130170A1
WO2018130170A1 PCT/CN2018/072194 CN2018072194W WO2018130170A1 WO 2018130170 A1 WO2018130170 A1 WO 2018130170A1 CN 2018072194 W CN2018072194 W CN 2018072194W WO 2018130170 A1 WO2018130170 A1 WO 2018130170A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
tumor necrosis
necrosis factor
factor alpha
seq
Prior art date
Application number
PCT/CN2018/072194
Other languages
English (en)
French (fr)
Inventor
朱乃硕
胡昌武
Original Assignee
朱乃硕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朱乃硕 filed Critical 朱乃硕
Priority to US16/477,488 priority Critical patent/US20230192768A1/en
Priority to JP2019559138A priority patent/JP7006968B2/ja
Publication of WO2018130170A1 publication Critical patent/WO2018130170A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Definitions

  • the invention belongs to the field of biotechnology, and particularly relates to a high affinity peptide (TNF ⁇ antagonist peptide) of tumor necrosis factor alpha (TNF ⁇ ) and application thereof.
  • TNF ⁇ antagonist peptide tumor necrosis factor alpha
  • Tumor necrosis factor was originally induced by endotoxin injection in 1975 and was identified as a serum active factor that induces apoptosis in tumors transplanted into mice, and was therefore named as tumor necrosis factor.
  • TNF ⁇ was found to be a very important inflammatory factor.
  • immune-induced inflammatory diseases the expression of TNF ⁇ in tissues increases, and induces a series of pathogenic reactions and expression of related inflammatory factors, ultimately leading to tissue damage, such as bone destruction, cartilage degradation, fibroblast proliferation. , keratinocyte proliferation, etc., make TNF ⁇ an important target for the treatment of a variety of inflammatory diseases.
  • the existing antagonists of TNF ⁇ mainly concentrate on monoclonal antibodies and monoclonal antibody-derived molecules, but the monoclonal antibody drugs are highly immunogenic, and can induce the production of anti-drug antibodies in the body, that is, the production of anti-antibodies, Questions may affect the efficacy of the drug, and on the other hand may induce antibody-dependent cell-mediated cytotoxicity and antibody-mediated complement-dependent cytotoxicity, which may cause damage and side effects to the body, due to anti-antibody production. The efficacy is reduced.
  • Different molecular structures determine the immunogenicity of the molecule.
  • the peptide is less immunogenic than the antibody, and the small molecular size makes the peptide substance more permeable. Therefore, the peptide is a more advantageous TNF ⁇ antagonist.
  • sequence-specific peptide was obtained by artificial synthesis, and the affinity of the antagonist peptide to TNF ⁇ was detected by ELISA. Then, the inflammatory animal was injected with the antagonist peptide, and it was convenient to observe whether the peptide has an inhibitory effect on inflammation. .
  • the TNF ⁇ high-affinity peptide provided by the present invention has the amino acid sequence as shown in SEQ.ID.NO.1, and is recorded as 632 peptide or TNF ⁇ antagonist peptide, and has the following functional characteristics: 1 can be highly affinity with TNF ⁇ , and the solution is determined.
  • the constant Kd reaches 138 nM (Kd value indicates the concentration of the ligand when half of the receptor is bound by the ligand, and the smaller the Kd value, the higher the affinity of the receptor to the ligand); 2 is effective after injection into an animal model of inflammation. It inhibits the onset of inflammation and acts as a resistance to inflammatory damage.
  • the present invention also provides a gene encoding the affinity peptide of the TNF ⁇ high affinity peptide (consisting of respective degenerate codons of the corresponding amino acids), the nucleotide sequence of which is shown in SEQ.ID.NO.2.
  • the present invention also obtains a peptide sequence having the same function as the TNF ⁇ high affinity peptide, and the amino acid sequence thereof is shown in SEQ.ID.NO.3 and is referred to as 636 peptide.
  • the present invention also provides a peptide sequence of SEQ.ID.NO.1 and an amino acid sequence of SEQ.ID.NO.3 which simultaneously contain the amino acid sequence of the TNF ⁇ high affinity peptide, which is a single or multiple repeated tandem or The branched peptide molecular sequence, and the molecule containing these core sequence features (homology above 70%), the peptide amino acid sequence is shown in SEQ.ID.NO.4.
  • the present invention also provides a peptide modified by biological and chemical groups, which comprises the TNF ⁇ high affinity peptides SEQ.ID.NO.1 and SEQ.ID.NO.3 as the C-terminus (or N-terminus of the core sequence, Structurally characteristic molecules to which a group or a side chain) is added with an antigen or a drug or a PEG modification or other molecular group covalently modified.
  • the present invention also provides a modified peptide comprising the above various TNF ⁇ high affinity peptides, wherein the TNF ⁇ high affinity peptide is modified by a fluorescent group such as FITC, isotopic labeling, chemiluminescent group or enzyme labeling reagent modification.
  • a fluorescent group such as FITC, isotopic labeling, chemiluminescent group or enzyme labeling reagent modification.
  • the molecule is used to detect TNF ⁇ .
  • the present invention also provides the use of the above various TNF ⁇ high affinity peptides for the preparation of TNF ⁇ antagonists.
  • the invention also provides the use of the above various TNF ⁇ high affinity peptides for detection and clinical detection of mucinous TNF ⁇ expression.
  • the invention also provides the use of a peptide gene having the nucleotide sequence of SEQ. ID. NO. 2 for the preparation of a TNF ⁇ antagonist and for use in tracer detection.
  • the peptide of the present invention having the amino acid sequence of SEQ.ID.NO.1 can be used as a TNF ⁇ antagonist drug.
  • the peptide has a strong affinity with TNF ⁇ , inhibits the biological activity of TNF ⁇ ., and resists TNF ⁇ -induced inflammatory damage.
  • the peptide of the present invention having the amino acid sequence of SEQ.ID.NO.3 can also be used as a potential TNF ⁇ antagonist drug, and the peptide also has strong affinity with TNF ⁇ and can inhibit the biological activity of TNF ⁇ .
  • Affinity test of the peptide with TNF ⁇ 96-well microtiter plate was coated with 2 ⁇ g/ml TNF ⁇ solution at 4 ° C overnight, and different concentrations of FITC-labeled 632 peptide were added and incubated for 2 h, then an anti-HRP-labeled anti-antigen was added.
  • FITC monoclonal antibody was incubated for 1 h, then added to ABTS coloring solution for 1 h, and the OD410 value was read by a microplate reader, and GraphPad Prism 5 was plotted and analyzed. As a result, it was confirmed that the 632 peptide has a strong affinity with the TNF ⁇ protein, and the dissociation constant Kd was 138 nM.
  • mice were divided into a blank group, an unrelated peptide control group, and an antagonist peptide group (632 peptide).
  • an antagonist peptide group (632 peptide).
  • mice were smeared with p-xylene on both sides of the right ear auricle.
  • the mice were sacrificed, the left and right ears were cut out, and the ears were removed using an ear swelling ear device.
  • the weight of the right ear of the same mouse was subtracted from the left ear. The ear weight is the degree of swelling of the mouse ear. Comparing the differences between the different groups, it was found that the peptide can significantly inhibit the swelling of the ear of the mouse, that is, the peptide can resist inflammation-induced damage.
  • the peptide has a strong affinity for the TNF ⁇ protein, and the peptide can resist TNF ⁇ -induced inflammatory damage, and thus can be used to inhibit the biological activity of TNF ⁇ , thereby promoting inflammatory diseases in which TNF ⁇ is strongly associated. To the therapeutic effect.
  • Figure 3 632 peptide inhibits the degree of inflammation in Kunming mice inflammation model.
  • the desired peptide is artificially synthesized by a chemical method, and the peptide has an affinity for the TNF ⁇ protein.
  • Lys (Dde)-WangResin was soaked in DCM for 10 min, then DCM was drained, then 25% by volume of 25% piperidine (piperidine/DMF) was added, and the piperidine was drained by bubbling with nitrogen for 20 min. DMF was added for 1 min, and after 6 cycles, it was drained, and the resin ninhydrin was detected to be blue.
  • the product was: H-Lys (Dde)-WangResin.
  • Three equivalents of Fmoc-Val-OH, HATU, DIEA in DMF were added to the resin.
  • the DMF reaction solution was drained, DMF was added and nitrogen was blown for 1 minute, and then drained, and the mixture was circulated three times, and the ninhydrin detection resin was transparent.
  • the product is: Fmoc-Val-Lys (Dde)-WangResin, and so on, to obtain a crude product. Purification was carried out on a Hanbang YCM C18 column using acetonitrile and Milli-Q water. Thereby, a peptide with high specificity and high activity is obtained.
  • Affinity test results of the peptide and TNF ⁇ protein 2 ⁇ g/ml of TNF ⁇ protein was coated overnight on a 96-well microtiter plate at 4° C., BSA was blocked, and different concentrations of 632 peptide with FITC-labeled peptide were added and co-incubated. 2h, HRP-labeled anti-FITC monoclonal antibody was added for 1 h, then ABTS coloring solution was added. After color development for 1 h, the OD410 value was read by a microplate reader, and GraphPad Prism 5 was used for mapping and analysis. As a result, it was confirmed that the 632 peptide has a strong affinity with the TNF ⁇ protein, and the dissociation constant Kd was 138 nM.
  • tumor necrosis factor alpha plays an important role in the development of inflammation.
  • TNF ⁇ increases and induces a series of pathogenic reactions and related.
  • cytokines causes tissue damage.
  • Antagonistic treatment of TNF ⁇ in various inflammatory diseases such as rheumatoid arthritis and psoriasis has proven to be an effective treatment.
  • current antagonists are concentrated on monoclonal antibodies and their derivatives, with strong side effects, especially immunogenicity, which limits drug use.
  • the TNF ⁇ high-affinity peptide provided by the present invention not only has strong affinity with TNF ⁇ , but also inhibits the biological activity of TNF ⁇ , thereby resisting related inflammatory damage, and can be used as a potential TNF ⁇ antagonist drug.
  • the modified 632 peptide can be used as a detection reagent to detect the expression of TNF ⁇ protein.
  • SEQ. ID. NO. 4 (N-terminal ⁇ C-terminal): HYIDFRWDMKASGSPSGFWPS.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种肿瘤坏死因子alpha的高亲和性肽，该肽的氨基酸序列为SEQ.ID.NO.1和SEQ.ID.NO.3所示，或者为SEQ.ID.NO.1和SEQ.ID.NO.3单次重复或多次重复的串联或分支的肽分子序列，其氨基酸序列为SEQ.ID.NO.4所示；该肽能和肿瘤坏死因子alpha高度亲力结合并可拮抗其功能。使用该肽直接注射动物，可显著降低动物体炎症的发生程度，提高动物体对炎症损伤的抵抗性。前述肽可用作开发肿瘤坏死因子alpha拮抗药物，治疗因各种急慢性炎症所造成的机体损伤，如各种物理、化学和生物因子所引起的炎性的、自身免疫和应激损伤，具有极其广泛的应用前景，且分子量小、免疫原性低、易于合成，避免了以往单克隆抗体药物拮抗剂的副作用和不足。

Description

一种肿瘤坏死因子alpha的高亲和性肽及其应用 技术领域
本发明属于生物技术领域，具体涉及一种肿瘤坏死因子alpha(TNFα)的高亲和性肽(TNFα拮抗肽)及其应用。
背景技术
肿瘤坏死因子开始是在1975年由内毒素注射而诱导产生，被鉴定为可诱导移植到小鼠体内的肿瘤凋亡的血清活性因子，因此才被命名为肿瘤坏死因子。随着研究的深入，发现TNFα是一种十分重要的炎症因子。在免疫反应诱发的炎症性疾病中，TNFα在组织中的表达上升，同时诱导一系列的病原性反应和相关炎症因子的表达，最终导致组织的损伤，例如骨骼破坏、软骨降解、成纤维细胞增殖、角质细胞增殖等等，使得TNFα成为治疗多种炎症性疾病的重要靶点。
TNFα已有的拮抗剂主要集中于单克隆抗体以及单克隆抗体衍生分子上，但是单克隆抗体药物的免疫原性强，在机体内可诱发抗药物抗体的产生，即抗抗体的产生，毫无疑问会影响药物疗效，另一方面还可能诱导抗体依赖的细胞介导的细胞毒作用和抗体介导的补体依赖的细胞毒作用，易于引起对机体的伤害和副作用，由于抗抗体产生也会使药效下降。不同的分子结构决定了分子的免疫原性，肽与抗体相比其免疫原性低，而且分子小使得肽类物质的组织渗透性更强，因此肽是一种更有优势的TNFα拮抗分子。采用人工合成的方法得到序列特异性的肽，使用ELISA方法检测拮抗肽与TNFα的亲和性，然后使用该拮抗肽注射炎症动物，可以很方便地观察到该肽是否具有对炎症发生的抑制作用。
发明内容
本发明的目的是提供一种肿瘤坏死因子alpha的高亲和性肽以及该亲和肽在拮抗肿瘤坏死因子alpha功能上的应用。
本发明提供的TNFα高亲和性肽，其氨基酸序列如SEQ.ID.NO.1所示，记为632肽或TNFα拮抗肽，具有如下功能特征：①可与TNFα高度亲和，测得解离常数Kd达到138nM (Kd值表示一半受体被配体结合时配体的浓度，Kd值越小代表受体与配体的亲和性越高)；②注射到炎症动物模型体内后可有效抑制炎症的发生，起到对炎症损伤的抵抗作用。
本发明还提供编码所述TNFα高亲和性肽的亲和肽的基因(由相应氨基酸各简并密码子构成)，其核苷酸序列如SEQ.ID.NO.2所示。
通过生物技术改造，本发明还获得了一种具有与所述TNFα高亲和性肽功能相同的肽序列，其氨基酸序列如SEQ.ID.NO.3所示，记为636肽。
本发明还提供一种同时含有TNFα高亲和性肽氨基酸序列的SEQ.ID.NO.1和氨基酸序列为SEQ.ID.NO.3的肽序列，为单次重复或多次重复的串联或分支的肽分子序列，及含有这些核心序列特征(同源性在70％以上)的分子，其肽氨基酸序列为SEQ.ID.NO.4所示。
本发明还提供一种经过生物和化学基团修饰的肽，其含有TNFα高亲和性肽SEQ.ID.NO.1和SEQ.ID.NO.3作为核心序列的C端(或N端，或侧链)基团上加抗原或药物或PEG修饰或其他分子基团共价修饰的结构特征分子。
本发明还提供一种经过修饰的肽，包括上述各种TNFα高亲和性肽，其TNFα高亲和性肽的加FITC等荧光基团修饰、同位素标记、化学发光基团或酶标试剂修饰的分子，用于检测TNFα。
本发明还提供上述各种TNFα高亲和性肽，在制备TNFα拮抗剂中的应用。
本发明还提供上述各种TNFα高亲和性肽，在黏TNFα表达检测和临床检测中的应用。
本发明还提供如核苷酸序列为SEQ.ID.NO.2的肽基因在制备表达TNFα拮抗剂中的应用和在示踪检测中的应用。
本发明的氨基酸序列为SEQ.ID.NO.1的肽可作为TNFα拮抗药物。该肽与TNFα具有很强的亲和性，可抑制TNFα.的生物学活性，抵抗TNFα诱导的炎症损伤。本发明的氨基酸序列为SEQ.ID.NO.3的肽同样可以作为潜在的TNFα拮抗药物，该肽同样与TNFα具有较强的亲和性，并可抑制TNFα的生物学活性。
该肽与TNFα亲和性实验：使用2μg/ml的TNFα溶液4℃过夜包被96孔酶标板，加入不同浓度的带有FITC标记的632肽后孵育2h，再加入带有HRP标记的抗FITC的单克隆抗体孵育1h，然后加入ABTS显色液显色1h，通过酶标仪读取OD410数值，GraphPad Prism5作图并分析。结果证实632肽与TNFα蛋白具有极强的亲和力，解离常数Kd为138nM。
该肽对炎症动物模型炎症发生程度的影响：将实验动物分为空白组、无关肽对照组和拮抗肽组(632肽)。以小鼠为例，使用6周大小的雄性昆明鼠，右侧腹部皮下注射，连续3天。最后一次注射后使用对二甲苯涂抹小鼠右耳耳廓两侧，1h后处死小鼠，剪下左右耳，使 用耳肿打耳器打下耳片，同一只小鼠的右耳重量减去左耳重量为鼠耳肿胀度。比较不同组之间的差异，发现该肽可以显著抑制小鼠耳部肿胀，即该肽可以抵抗炎症诱导的损伤。
由此可见，该肽对TNFα蛋白具有极强的亲和性，而且该肽可以抵抗TNFα诱导的炎症损伤，因此可以用以抑制TNFα生物活性的发挥，从而在TNFα强烈相关的炎症性疾病中起到治疗作用。
附图说明
图1 632肽对TNFα蛋白的亲和性。
图2 636肽对TNFα蛋白的亲和性。
图3 632肽抑制昆明小鼠炎症模型炎症发生的程度。
具体实施方式
一、肽序列的获得与改造
通过化学的方法人工合成所需的肽，肽具有与TNFα蛋白亲和的作用。
二、肽的合成与纯化
Lys(Dde)-WangResin用DCM浸泡10min后抽干DCM，然后加入树脂体积三倍的25％哌啶(哌啶/DMF)，用氮气鼓吹20min后抽干哌啶。加入DMF鼓吹1min，循环6次后抽干，取树脂茚三酮检测呈蓝色。产物为：H-Lys(Dde)-WangResin。加入树脂3倍当量的Fmoc-Val-OH，HATU，DIEA在DMF中。用氮气鼓吹20min后抽干DMF反应液，加入DMF用氮气鼓吹1min后抽干，循环3次，茚三酮检测树脂呈透明。产品为：Fmoc-Val-Lys(Dde)-WangResin，依次类推，得到粗产品。用乙腈、Milli-Q水通过汉邦YCM C18柱子进行纯化。从而获得高特异性、高活性的目的肽。
三、632肽与TNFα的亲和试验及对动物模型炎症发生程度的影响
1、该肽与TNFα蛋白亲和性实验结果：将2μg/ml的TNFα蛋白4℃过夜包被在96孔酶标板上，BSA封闭后加入不同浓度的带有FITC标记的632肽，共孵育2h，加入带HRP标记的抗FITC的单克隆抗体孵育1h，然后加入ABTS显色液，显色1h后通过酶标仪读取OD410数值，GraphPad Prism 5作图并分析。结果证实632肽与TNFα蛋白具有极强的亲和力，解离常数Kd为138nM。
2、该肽对炎症动物模型炎症发生程度的影响：将实验动物分为空白组、无关肽对照组和拮抗肽组(632肽)。使用6周大小的雄性昆明鼠，右侧腹部皮下注射肽，连续3天。末次 注射后30min，各组动物用对二甲苯0.03ml/只涂于小鼠右耳廓两面致炎，左耳不涂作为正常耳。致炎1h后处死动物，完整剪下小鼠耳朵并做好标记，区分同一只小鼠的左右耳。使用同一张纸包裹住鼠耳两面，用直径8mm的耳肿打孔器打下双耳相同部位耳片，连同白纸一起置于天平上称重，记录数值。鼠耳肿胀度＝致炎侧耳片重一非致炎侧耳片重。
结果发现，632肽与TNFα蛋白具有极强的亲和作用。动物实验结果表明，注射632肽的实验组动物的鼠耳肿胀度显著小于对照组。以上结果说明632肽可以通过拮抗TNFα活性的发挥，从而达到抵抗炎症损伤的效果。如图1、图2所示。
四、具体应用
肿瘤坏死因子alpha作为一种重要的炎症因子，在炎症发生发展的过程中起到了十分重要的作用，而在炎症诱导的免疫性疾病中，TNFα表达上升的同时诱导一系列的病原性反应和相关细胞因子的表达，造成组织损伤。多种炎症性疾病，例如风湿性关节炎、银屑病等中对TNFα的拮抗治疗已被证实为有效的治疗方式。但是目前的拮抗物集中在单克隆抗体及其衍生物上，副作用中强，尤其是免疫原性，限制了药物使用。因此本发明提供的TNFα高亲和性肽除了与TNFα亲和力强以外，还可以抑制TNFα生物活性的发挥，从而抵抗相关的炎症损伤，可作为潜在的TNFα拮抗药物。另外经过修饰的632肽，可以作为检测试剂检测TNFα蛋白的表达。
序列表
SEQ.ID.NO.1(N端→C端)：HYIDFRW
SEQ.ID.NO.2：CATTATATTGATTTTAGGTGG
SEQ.ID.NO.3(N端→C端)：KASGSPSGFWPS
SEQ.ID.NO.4(N端→C端)：HYIDFRWDMKASGSPSGFWPS。

Claims (7)

  1. 一种肿瘤坏死因子alpha的高亲和性肽，其特征在于，氨基酸序列为SEQ.ID.NO.1和SEQ.ID.NO.3之一；或者为SEQ.ID.NO.1和SEQ.ID.NO.3单次重复或多次重复的串联或分支的肽分子序列，其氨基酸序列为SEQ.ID.NO.4。
  2. 一种编码氨基酸序列为SEQ.ID.NO.1的肿瘤坏死因子alpha的高亲和性肽的基因，其特征在于，核苷酸序列为SEQ.ID.NO.2所示。
  3. 一种经过生物和化学基团修饰的肽，其特征在于，含有如权利要求1所述的肿瘤坏死因子alpha高亲和性肽作为核心序列的C端，或N端，或侧链基团上加抗原或药物或PEG修饰或其他分子基团共价修饰的结构特征分子。
  4. 一种经过修饰的肽，其特征在于，如权利要求1所述的肿瘤坏死因子alpha的高亲和性肽，其肿瘤坏死因子alpha高亲和性肽的加FITC荧光基团修饰、同位素标记、化学发光基团或酶标试剂修饰的分子，用于检测肿瘤坏死因子alpha。
  5. 如权利要求1所述的肿瘤坏死因子alpha高亲和性肽在制备肿瘤坏死因子alpha拮抗剂中的应用。
  6. 如权利要求1所述的肿瘤坏死因子alpha高亲和性肽在制备肿瘤坏死因子alpha表达检测物和临床检测物中的应用。
  7. 如权利要求2所述的肿瘤坏死因子alpha的高亲和性肽的基因在制备表达肿瘤坏死因子alpha拮抗剂中的应用和在示踪检测中的应用。
PCT/CN2018/072194 2017-01-12 2018-01-11 一种肿瘤坏死因子alpha的高亲和性肽及其应用 WO2018130170A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/477,488 US20230192768A1 (en) 2017-01-12 2018-01-11 High-affinity peptide for tumor necrosis factor alpha and application thereof
JP2019559138A JP7006968B2 (ja) 2017-01-12 2018-01-11 腫瘍壊死因子αの高親和性ペプチド及びその適用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710019149.8 2017-01-12
CN201710019149.8A CN106831944A (zh) 2017-01-12 2017-01-12 一种肿瘤坏死因子alpha的高亲和性肽及其应用

Publications (1)

Publication Number Publication Date
WO2018130170A1 true WO2018130170A1 (zh) 2018-07-19

Family

ID=59117361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/072194 WO2018130170A1 (zh) 2017-01-12 2018-01-11 一种肿瘤坏死因子alpha的高亲和性肽及其应用

Country Status (4)

Country Link
US (1) US20230192768A1 (zh)
JP (1) JP7006968B2 (zh)
CN (1) CN106831944A (zh)
WO (1) WO2018130170A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831944A (zh) * 2017-01-12 2017-06-13 复旦大学 一种肿瘤坏死因子alpha的高亲和性肽及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026744A1 (en) * 1994-04-01 1995-10-12 Centocor, Inc. Tumor necrosis factor inhibitors
WO2000021981A2 (de) * 1998-10-09 2000-04-20 Bioserv Ag TNFα BINDENDE PEPTIDE UND IHRE ANWENDUNG FÜR DIE DETEKTION, INAKTIVIERUNG UND/ODER ENTFERNUNG VON TNFα AUS BIOLOGISCHEN FLÜSSIGKEITEN
US6344443B1 (en) * 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
CN101747414A (zh) * 2008-12-19 2010-06-23 华中科技大学 TNF-α结合肽和TNFR1封闭肽及其在治疗TNF相关疾病中的应用
CN104804069A (zh) * 2014-12-31 2015-07-29 钟英强 趋化因子受体5拮抗剂及药物组合物
CN106518968A (zh) * 2016-11-08 2017-03-22 华东理工大学 壳聚糖亲和七肽及其筛选方法和应用
US20170101442A1 (en) * 2015-10-07 2017-04-13 Kun Cheng Peptide Ligands for Hepatic Stellate Cells
CN106831944A (zh) * 2017-01-12 2017-06-13 复旦大学 一种肿瘤坏死因子alpha的高亲和性肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143865C (zh) * 2001-04-20 2004-03-31 中国人民解放军军事医学科学院基础医学研究所 肿瘤坏死因子-α抑制肽及其应用
JP2005145884A (ja) * 2003-11-14 2005-06-09 Peptide Door Co Ltd ＴＮＦ−αに結合性を有するペプチド又はタンパク質、及び該ペプチド又はタンパク質を用いたＴＮＦ−α吸着体、ＴＮＦ−α検査試薬、ＴＮＦ−α中和剤
SG171348A1 (en) * 2008-11-20 2011-07-28 Panacea Biotec Ltd Tumor necrosis factor alpha inhibiting peptides and uses thereof
CN104829697B (zh) * 2015-05-04 2018-09-04 国家纳米科学中心 一种与肿瘤坏死因子结合的多肽及其应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026744A1 (en) * 1994-04-01 1995-10-12 Centocor, Inc. Tumor necrosis factor inhibitors
US6344443B1 (en) * 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
WO2000021981A2 (de) * 1998-10-09 2000-04-20 Bioserv Ag TNFα BINDENDE PEPTIDE UND IHRE ANWENDUNG FÜR DIE DETEKTION, INAKTIVIERUNG UND/ODER ENTFERNUNG VON TNFα AUS BIOLOGISCHEN FLÜSSIGKEITEN
CN101747414A (zh) * 2008-12-19 2010-06-23 华中科技大学 TNF-α结合肽和TNFR1封闭肽及其在治疗TNF相关疾病中的应用
CN104804069A (zh) * 2014-12-31 2015-07-29 钟英强 趋化因子受体5拮抗剂及药物组合物
US20170101442A1 (en) * 2015-10-07 2017-04-13 Kun Cheng Peptide Ligands for Hepatic Stellate Cells
CN106518968A (zh) * 2016-11-08 2017-03-22 华东理工大学 壳聚糖亲和七肽及其筛选方法和应用
CN106831944A (zh) * 2017-01-12 2017-06-13 复旦大学 一种肿瘤坏死因子alpha的高亲和性肽及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN, Z.J. ET AL.: "Discovery of Peptide Ligands for Hepatic Stellate Cells Using Phage Display", MOL. PHARM., vol. 12, no. 6, 1 June 2015 (2015-06-01), pages 2180 - 2188, XP055465636, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.5b00177 *
HU , CHANGWU ET AL.: "Comparison of the Inhibitory Efficiency of M13 Based 7-mer and 12-mer Phage Display Libraries Derived Peptides as Tumor Necrosis Factor Alpha Antagonist", CHINA BIOTECHNOLOGY, vol. 37, no. 5, 31 December 2017 (2017-12-31), pages 1 - 8, XP055613670, DOI: 10.13523/j.eb.20170501 *
LIU, SIXUE ET AL.: "Panning and Identification of Antagonistic Active Peptides Specifically Bin-Ding to the First and Second Extracellular Membrane Loops of Rat CCR5 by Technique of Phage Display Peptide Library", CHINESE JOURNAL OF PATHOPHYSIOLOGY, vol. 31, no. 7, 31 December 2015 (2015-12-31), pages 1225 - 1230, XP009515547, ISSN: 1000-4718 *
YOU, F. ET AL.: "Biopanning and Characterization of Peptides with Fe304 Nanoparticles-Binding Capability via Phage Display Random Peptide Library Technique", COLLOIDS AND SURFACES B: BIOINTERFACES, 2 February 2016 (2016-02-02), pages 537 - 545, XP029465880, ISSN: 0927-7765, DOI: 10.1016/j.colsurfb.2016.01.062 *

Also Published As

Publication number Publication date
JP7006968B2 (ja) 2022-02-10
JP2020505060A (ja) 2020-02-20
CN106831944A (zh) 2017-06-13
US20230192768A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
DeLuca-Flaherty et al. Uncoating protein (hsc70) binds a conformationally labile domain of clathrin light chain LCa to stimulate ATP hydrolysis
KR101151805B1 (ko) 바이포달 펩타이드 바인더
JP6974874B2 (ja) ヒトｐｄ−ｌ１タンパク質に高親和性を有するペプチド及びその使用
MX2014015825A (es) Proteinas de repeticion de anquirina diseñadas que se unen al factor de crecimiento derivado de plaquetas.
US20100016549A1 (en) Peyer's patch and/or m-cell targeting ligands
Di Matteo et al. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif
US20180201653A1 (en) Polypeptide compound and preparation method and use thereof
Real Fernández et al. Antibody recognition in multiple sclerosis and Rett syndrome using a collection of linear and cyclic N‐glucosylated antigenic probes
CN104163852A (zh) 与人mhc-i类分子结合的ecm1多肽表位
WO2014161370A1 (zh) 鱼精蛋白模拟肽及其药用盐与应用
WO2018130170A1 (zh) 一种肿瘤坏死因子alpha的高亲和性肽及其应用
CN110420334A (zh) 一种药物缀合物和提高药物分子半衰期的方法
Sun et al. A novel Nogo-66 receptor antagonist peptide promotes neurite regeneration in vitro
US20060286611A1 (en) Antibodies against biotinylated histones and related proteins and assays related thereto
KR20180086277A (ko) 폴리펩티드 화합물, 그리고 이의 제조 방법 및 적용
CN106589062B (zh) 靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用
KR101323846B1 (ko) 타겟 친화도가 유지되고 안정성이 개선된 ｄ－앱타이드
Li et al. Chemical modification of cellulose membranes for SPOT synthesis
Vaisman et al. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library
Sala et al. Design, Synthesis, Biological Activity, and Structural Analysis of Lactam‐Constrained PTPRJ Agonist Peptides
Sinclair Utilizing Chemical Biology to Interrogate Two Key Coiled-Coil Motifs in The Epidermal Growth Factor Receptor
Li et al. Screening TLR4 Binding Peptide from Naja atra Venom Glands Based on Phage Display
Wen et al. Screening of Peptides that Specifically Binds to M3-M4 Extracellular Domain of Sodium Pump α1 Subunit and Analysis of Their Bioactivity In Vitro and In Vivo
Elko et al. COVID-19 vaccination recruits and matures cross-reactive antibodies to conserved epitopes in endemic coronavirus Spike proteins
Rodrigues Design and Synthesis of Hyaluronan: RHAMM Interaction Inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18738565

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019559138

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018738565

Country of ref document: EP

Effective date: 20190812

122 Ep: pct application non-entry in european phase

Ref document number: 18738565

Country of ref document: EP

Kind code of ref document: A1